Background: To define a maximum tolerated dose (MTD) for the combination of epirubicin and cyclophosphamide with filgrastim (r-met-HuG-CSF) in patients with advanced solid tumors and non-Hodgkin's lymphoma (NHL).
Introduction
The development of autologous bone marrow and peripheral blood stem-cell transplantation has provided evidence that substantially increased doses of chemotherapeutic agents can result in increased survival in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease [1, 2] . However, whether a dose-response effect exists in terms of tumor response and overall survival with non-myeloablative regimens is still largely unproven for both solid tumors and hematological malignancies.
Anthracyclines and alkylating agents have activity in a wide variety of tumors. Dose-escalation of these drugs in NHL is particularly relevant for two reasons: a doseresponse relationship for the drug combination of doxorubicin and cyclophosphamide has been suggested [3] , and third generation multi-agent regimens have not been shown to be superior to standard-dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) [4] . The administration of multiple cycles of dose-escalated, but non-myeloablative chemotherapy without growth factor support has, however, been prevented by the intense myelosuppression resulting from these regimens. There is enough evidence to suggest that growth factors may have a role in ameliorating myelosuppression in this context. Granulocyte-colony stimulating factor (G-CSF) acts to stimulate myelopoiesis [5] and in randomized studies using moderately dose-intense chemotherapy decreases the incidence of severe neutropenia and neutropenic fever requiring hospitalization and intravenous antibiotics [6] , Alkylating agents are suitable for dose-escalation with G-CSF support as their main dose-limiting toxicity (DLT) is myelosuppression. This is in contrast to anthracyclines, in particular doxorubicin, where dose-escalation has been difficult due to non-hematological toxicities, predominantly mucosal and cardiac [7, 8] . However, some of the newer anthracyclines, in particular epirubicin, the 4-OH epimer of doxorubicin, appear to produce less mucositis and cardiotoxicity than the parent compound [9] . As a single agent without G-CSF, maximum tolerated doses (MTD) of epirubicin up to 165-180 mg/m 2 every three weeks for untreated patients, and 150 mg/m 2 every three weeks for previously treated patients have been described with neutropenia as the DLT [10] [11] [12] [13] .
The purpose of this study was to determine if filgrastim used in conjunction with epirubicin and cyclophosphamide would allow significant dose-escalation of these agents with acceptable hematological and non-hematological toxicity. This premise was to be tested by parallel dose escalation of the two drugs in patients with advanced solid tumors, with subsequent treatment of patients with NHL with the maximum tolerated dose (MTD) of the drug combination.
Patients and methods
A phase I open, non-controlled, non-randomized, unblinded, multicentre study of sequential dose escalation of multiple cycles of epirubicin/cyclophosphamide with filgrastim in patients with advanced solid tumors was performed to determine a MTD. The phase I component consisted of two stages, I and II. Subsequently a phase II study using the MTD derived from the phase I study was performed in patients with untreated NHL and termed stage III of the study. The Ethics Committee of each participating institution approved the study protocols and written informed consent was obtained. Patients were treated between August 1991 and October 1995.
Diagnosis and criteria for inclusion
All patients in stages I and II had a histological diagnosis of advanced cancer for which epirubicin may be indicated. Patients in stage III of the study had intermediate or high grade NHL and had received no prior cytotoxic therapy. Protocol patients were required to have an ECOG performance status ^2 and were aged between 18 and 70 years. Adequate baseline organ function was necessary, documented by creatinine < 176 umol/l (2.0 mg/dl), bilirubin <35 umol/l (2.0 mg/dl) and AST (SGOT) < 3 x upper normal limit, normal bone marrow function with granulocytes > 2.0 x 10 9 /l and platelets > 100 x 10 9 /l, and a normal baseline left ventricular ejection fraction (LVEF) on multiple gated acquisition scan (MUGA). Patients may have received prior radiotherapy, provided it did not involve > 35% of red bone marrow and they had recovered from any acute radiationinduced toxicities. Patients were required to be able to comply with scheduled follow-up visits.
Patients were excluded if they had any significant cardiac history or ECG changes, a history of other malignancy other than localised basal or squamous cell carcinoma of the skin or non-invasive cervical cancer, clinical or radiological evidence of brain metastases, evidence of an active infectious process, evidence of myeloid malignancy, psychiatric disorders compromising informed consent, or if they were either pregnant or currently breast feeding.
Pretreatment evaluations included complete medical history and physical examination, histological or cytological confirmation of the disease, chest X-ray, bone scan where clinically indicated, bone marrow biopsy in patients with NHL, computed tomographic (CT) scan of head, chest and abdomen for solid tumor patients or CTscan of chest, abdomen and pelvis for patients with NHL, urinalysis, full blood examination (FBE). renal and liver function tests, electrocardiogram (ECG) and a MUGA scan.
Definitions
DLT was defined as either persistent neutropenia (failure to reach an ANC > 2 x 10 9 /l) despite protracted filgrastim therapy, or persistent thrombocytopenia (failure to reach platelets > 100 x 1O 9 /1) by day 36 from the previous cycle, or any grade 4 adverse event (World Health Organization Common Toxicity Criteria (CTC)) [14] with the exceptions of transient hematological toxicity (neutrophils <0.2 x 10 9 /l for 5 days independent of platelet transfusion and in the absence of hemorrhagic episodes), antibiotic responsive neutropenic fever if ^ 4 days duration from the start of intravenous antibiotics, pain and vomiting. Patients were assessed a minimum of three times a week for neutropenic fever which was defined as neutrophils <0.5 x 10 9 /l and oral temperature > 38 °C on three consecutive occasions in a 24-hour period or a single oral temperature > 38.5 °C. Grade 4 neutropenia was defined as a neutrophil nadir <0.5 x 1O 9 /1, and grade 4 thrombocytopenia as a platelet nadir < 25 x 10 9 /l. Maximum tolerated dose (MTD) of epirubicin-cyclophosphamide was defined as the dosage level immediately below that which resulted in three patients experiencing DLT. A minimum of three patients had to be enrolled in each treatment cohort. If one or more of the three patients at a particular dosage level experienced either a DLT or grade 3 mucositis, sepsis, diarrhoea or persistent neutropenia (ANC <2 x 10 9 /l at day 21), at least three extra patients were accrued for that dosage level. Safety criteria were as described for DLTs. Patients were evaluated three times a week to assess recovery from hematological and nonhematological toxicity. Cardiac function was monitored with the evaluation of LVEF by MUGA scan prior to entry onto the study and once per cycle if LVEF < 10% below normal or when cumulative dose reached 350-500 mg/m 2 , 600-670 mg/m 2 and before each cycle thereafter.
Treatment regimen

Stage I
Eligible patients were treated in sequential cohorts of at least three patients at increasing dosage levels of cyclophosphamide/epirubicin (at a dosage ratio of 10:1 for cyclophosphamide-epirubicin) to determine a MTD for epirubicin. The starting doses were epirubicin 90 mg/m 2 and cyclophosphamide 900 mg/m 2 and doses escalated by 30 mg/m 2 of epirubicin in each cohort with concurrent increases of 300 mg/m 2 of cyclophosphamide. Up to six cycles of treatment were administered every twenty-one days. There were no intrapatient dose escalations. All patients received three litres of intravenous fluid on the day of treatment. One litre of normal saline was administered prechemotherapy, followed by cyclophosphamide diluted in 1 1 of normal saline and infused over 60 minutes. The epirubicin was diluted in 500 ml normal saline and infused over 30 minutes.
Stage II
Cyclophosphamide was further dose escalated using the MTD established for epirubicin from stage I. New cohorts of three or more patients were treated at 21-day intervals with the epirubicin dose held at 150 mg/m 2 and escalation of the cyclophosphamide dose by 300 mg/m 2 to determine a MTD for cyclophosphamide. As for stage I, the number of patients per cohort could be increased from three to at least six, if one or more patients experienced toxicity.
Stage III
Stage III used the maximum dose level from stages I and II which was thought to be deliverable over six cycles (epirubicin 150 mg/m 2 , cyclophosphamide 1500 mg/m 2 ; cohort 3, stage I). This cohort consisted of 21 patients with NHL. These patients also received intravenous vincristine 2 mg total dose on day 1 and oral prednisolone 100 mg per day for five days commencing on day 1. Cycles were given at 21-day intervals for six cycles.
Anti-emetics
The anti-emetic protocol utilized consisted of a 5-HT 3 antagonist, generally ondansetron 8 mg and dexamethasone 8 mg intravenously pre-chemotherapy with oral ondansetron and/or metoclopramide for two to three days post-chemotherapy.
Filgrastim
Filgrastim (r-met-HuG-CSF) was administered routinely to all patient cohorts at a dose of 5 ug/kg/day subcutaneously from days 2-12 and was ceased thereafter once the neutrophil count was > 10.0 x 1O 9 /1 on two consecutive measurements 24 hours apart.
Hematohgical monitoring
Full blood examination including white cell count with complete manual differential was performed at initial screening, baseline, prior to delivery of each cycle of chemotherapy, every second day during treatment and at study termination or completion. Platelet transfusions were given for platelets <20 x 10 9 /l. Red blood cell transfusions were given for a hemoglobin level of $ 8 0 g/1 or $ 9 0 g/1 in patients with symptoms of anemia.
Dose reductions
A 25% dose reduction of both epirubicin and cyclophosphamide for subsequent treatments occurred for any of the following: non-hematological grade 4 toxicity, failure to reach neutrophils >2.0 x 10 9 /l or platelets > 100 x 10 9 /l by day 36, severe neutropenia (neutrophils <0.2 x 10 9 /l) or neutropenic fever of at least four days duration or when associated with severe hypotension. The level of thrombocytopenia that resulted in dose reduction was < 50 x 10 9 /l in stages I and II and <25 x 10 9 /l in stage III.
Criteria for evaluation
Efficacy criteria
Patients who received one or more courses of chemotherapy with at least one dose of filgrastim were evaluated for toxicity and response. Tumor response was not an endpoint of this study (stages I and II), therefore measurable disease was not stipulated and detailed lesion measurements were not required. However, disease response or progression was documented in stage III after each cycle. Complete response (CR) was defined as (i) the disappearance of all known disease determined by two observations at least one month apart or (ii) a residual mass less than 50% of the maximum two-dimensional pretreatment size, which remained stable in size for at least two to four months after the end of treatment and was not gallium avid [15] . Partial response (PR) was defined as a greater than 50% reduction in tumor size for at least one month. No change (NC) signified no significant change for at least four weeks and included stable disease, estimated decrease of less than 50% and lesions with increase of less than 25%. Progressive disease (PD) was defined as 25% or greater increase in the size of one or more measurable lesions or the appearance of new lesions. Disease could also be not evaluated (NE).
Withdrawal from treatment
Patients could be removed from the study after successful completion of six cycles of treatment, disease progression or a requirement for alternative therapy, unacceptable or dose-limiting toxicity, treatment delays of as much as three weeks, or a decision by the investigator that cessation was in the patient's best medical interest.
Statistical methods
For each cohort in stages I and II, hematological and non-hematological DLTs were recorded in order to identify the MTD of cyclophosphamide plus epirubicin. Descriptive statistics were generated for each 
Results
Patient characteristics
The characteristics and tumor types of the 35 patients enrolled in stages I and II are listed in Table 1 . Twentytwo patients were entered into stage I, but only twentyone were evaluated as one patient withdrew consent prior to commencing treatment. Three patients were treated in cohort 1 and six in each of cohorts 2-4. No patients were treated beyond cohort 4 (epirubicin 180 mg/m 2 , cyclophosphamide 1800 mg/m 2 ) due to three DLTs occurring in this cohort.
Fourteen patients were enrolled in stage II. This stage comprised two cohorts of patients -eight patients in cohort 1 (epirubicin 150 mg/m 2 , cyclophosphamide 1800 mg/m 2 ) and six patients in cohort 2 (epirubicin 150 mg/m 2 , cyclophosphamide 2100 mg/m 2 ). Twenty-two patients were enrolled in stage III of the study. Twenty-one had a histologically confirmed diagnosis of NHL, and one further patient was enrolled but excluded after subsequent review indicated the patient had an undifferentiated carcinoma. The characteristics and lymphoma subtypes of the patients enrolled in stage III are listed in Table 2 .
Hematological toxicity
Stages land II Neutropenia. The incidence of CTC grade 4 neutropenia in stages I and II is outlined in Table 3 . DLT Abbreviations: DLCL -Diffuse large-cell lymphoma; DML -diffuse mixed-cell lymphoma; D/FLCL -diffuse and follicular large-cell lymphoma; LCL -large-cell lymphoma; FSCCL -follicular smallcleaved-cell lymphoma; NHL -non-Hodgkin's lymphoma; LDHlactate dehydrogenase; ECOG -Eastern Cooperative Oncology Group. " Not available for one patient. b Age adjusted International Index [16] . related to neutropenia was experienced in two patients enrolled on cohort 4 of stage I. Both patients were admitted with neutropenic fever requiring more than four days of intravenous antibiotics. One other patient in this cohort was febrile and neutropenic. There were three other episodes of neutropenic fever, two in cohort 2 and one from cohort 3. In total, neutropenic fever occurred in 6 of the 76 treatment cycles (8%) in stage I. Neutropenic fever occurred in 5 of the 45 treatment cycles (11%) in stage II, two episodes in cohort 1 and three in cohort 2.
Thrombocytopenia. The incidence of thrombocytopenia (platelets < 50 x 10 9 /l, the level at which subsequent dose reduction was specified) for patients enrolled in stages I and II are presented in Table 4 . Thrombocytopenia increased with the dose level in stage I, resulting in both dose reductions for subsequent cycles and inability to deliver multiple treatment cycles for cohort 4 patients. Dose reductions due to thrombocytopenia did not occur until cycle 4 in cohorts 1-3. However, in cohort 4 dose reductions were required for the majority of patients due to thrombocytopenia following the first treatment cycle (Tables 4 and 5 ). In stage II dose escalation was ceased after six patients had been registered on cohort 2 (epirubicin 150 mg/m 2 , cyclophosphamide 2100 mg/m 2 ) as thrombocytopenia resulted in the inability to administer more than two cycles without dose reduction. Table 3 . Eighty-five of one hundred eighteen cycles (72%) resulted in a neutrophil nadir < 0.5 x 10 9 /l, and in fifty-five of one hundred eighteen cycles (47%) a nadir of <0.1 x 10 9 /l. Median duration of neutropenia (<2.0 x 10 9 /l) for cycle 1 was 5 days (range 1-8), compared with three days for cycle 6 (range 0-6). Neutropenic fever was documented for seventeen of 21 patients (81%) during at least one cycle of treatment and occurred in a total of 34 of 118 cycles (29%). Neutropenic fever occurred in 14 of 21 treatments (67%) for cycle 1 compared with 20 of 97 treatments (19%) for cycles 2-6. Dose reductions were required in six of those episodes due to prolonged neutropenic fever. No patient died of sepsis.
Hemoglobin.
Thrombocytopenia. The criteria for thrombocytopenia requiring dose-modification or treatment delay was changed to a platelet level <25 x 10 9 /l for stage III. This was seen in twelve of 118 cycles (12%), five of which occurred with the sixth cycle ( Table 4) . Severity of thrombocytopenia increased with cycle number. Median duration of thrombocytopenia, platelets < 100 x 1O 9 /1 for cycle 1 was 3 days (range 0-15) compared with a median of 8 days (range 5-20) for cycle 6. Platelet transfusions were required on nine occasions for eight patients and were not cycle dependent. No significant bleeding occurred.
Hemoglobin. A total of 97 units of packed cells were transfused in 18 of 21 stage III patients. The requirement for transfusion was not cycle dependent.
Cytokine administration
Filgrastim was administered for a median of 14 days (range 10-18.5) in stages I and II, and for a median of 13 days (range 10-17) to patients in stage III. There was no difference in median duration between cycles. Abbreviations: CTC -common toxicity criteria; Epi -epirubicin; cyclo -cyclophosphamide. mucositis with cycle 1. The other patient had a grade 4 gastrointestinal microbial infection with diarrhoea during cycle 1 and received a further three dose-reduced cycles of therapy. Grade 3 toxicities including nausea, vomiting, stomatitis and cardiac toxicity were experienced in 21 out of a total of 123 cycles. Of the patients entered on stages I and II, one patient developed apical hypokinesis on MUGA scan after completion of six cycles of chemotherapy. Three patients developed atrial tachyarrhythmias, from which they recovered. One patient developed angina and required hospitalization.
Other toxicities
Stage III. Grade 3 toxicity for nausea, vomiting, stomatitis and diarrhoea occurred in two, one, one, and no patients respectively for stage III. No other grade 3 and no grade 4 toxicities occurred. One patient developed cardiac failure during the first cycle of therapy in association with a febrile neutropenic episode. The LVEF prior to treatment had been 62%, and the patient was withdrawn after two cycles due to disease progression. Seventeen of 19 patients completing six treatment cycles had a repeat MUGA scan at the time of the fifth or sixth cycle. In three of these, a fall in LVEF of Ss 12% (12%, 12%, 15%) was observed, but this did not equate to a final value below normal limits. Only one of these patients had a follow up scan at two months post completion of therapy, at which time the LVEF was unchanged. None of these patients had symptoms of congestive cardiac failure. Two of the three patients with a > 12% fall in LVEF received radiation therapy; one patient had mantle field and the other involved field radiation involving the lung fields. Five additional patients had follow-up measurements of LVEF up to six months post treatment with stable LVEF's documented and no patients to this time have developed symptomatic cardiac failure.
Fertility
Formal documentation of fertility was not included in the protocol. In stage III, the fertility of three premenopausal women and four men were evaluated at one institution. The three women (aged 28-31) experienced menopausal symptoms early post chemotherapy. All had luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels within the menopausal range. Symptoms necessitated temporary institution of hormone replacement therapy, which was withdrawn following documentation of normal FSH and LH levels after 9-23 months. One of these women subsequently had a normal pregnancy two years after completing chemotherapy. The four males (aged 39-44) had subnormal sperm counts post chemotherapy. Two had azoospermia at 4 and 47 months post treatment, and two oligospermia (8, and 13 x 10 6 /ml: normal >20 x 10 6 /ml) when tested at two years.
Treatment delays
A total of 25 cycles in 13 patients were delayed in stage I. Five delays occurred in cohort 1, two in cohort 2, eight in cohort 3 and ten in cohort 4. The delays were for a combination of reasons including neutropenia < 0.5 x 10 9 /l in the absence of fever (11 cycles) and with fever (2 cycles), logistical reasons (6 cycles), patient request (3 cycles), thrombocytopenia (1 cycle), tumor progression associated with uncontrolled pain (1 cycle) and tumor progression requiring radiotherapy (1 cycle). Six patients experienced delays in a total of nine cycles in stage II due to logistical reasons (seven cycles), grade 3 diarrhoea (one cycle) and an intercurrent non-neutropenic febrile illness (one cycle).
A delay in commencing treatment in stage III occurred in 22 cycles as a result of logistical reasons, most commonly due to incomplete restaging and lack of bed availability, and an infected biopsy site in one. The reason was not able to be determined for delay in two other cycles. Only one delay was documented resulting from inadequacy from neutrophil recovery.
Dose reductions and dose intensity
In stage I, nine patients required dose reductions in 14 cycles due to thrombocytopenia. In stage II, seven patients required dose reductions in 14 cycles due to thrombocytopenia (12 cycles), and in two as a result of grade 4 mucositis and non-neutropenic septicemia.
Nineteen of twenty-one patients (90%) completed six cycles of therapy in stage III, in eight (38%) without a dose reduction of epirubicin or cyclophosphamide. Two patients were withdrawn after two cycles because of progressive or minimally responsive disease. Dose reductions of epirubicin and cyclophosphamide or vincristine occurred in 33 of 118 (28%) of all cycles administered. Reductions were instituted because of neutropenic fever (6 cycles), thrombocytopenia <25 x 1O 9 /1 (12 cycles) and vincristine-related neurotoxicity (3 cycles). The actual dose intensity delivered for all 118 cycles was 422 mg/m 2 /wk of cyclophosphamide (85% of the predicted dose of 500 mg/m 2 /wk) and 42.2 mg/m 2 /wk for epirubicin (85% of the predicted dose of 50 mg/m 2 /wk).
Determination of maximum tolerated doses (MTD)
DLTs were experienced in three patients on stage I, cohort 4 (epirubicin 180 mg/m 2 , cyclophosphamide 1800 mg/m 2 ). Two of these events involved prolonged neutropenic fever (> 4 days duration), the other related to grade 4 diarrhoea. The MTD for epirubicin in conjunction with cyclophosphamide was therefore determined to be epirubicin 150 mg/m 2 and cyclophosphamide 1500 mg/m 2 . No DLTs were seen at this dose level. In stage II further dose-escalation of cyclophosphamide was ceased after six patients had been registered on cohort 2 (epirubicin 150 mg/m 2 , cyclophosphamide 2100 mg/m 2 ). One DLT of grade 4 mucositis was observed, but thrombocytopenia (platelet level < 50 x 10 9 /l) resulted in dose reductions and an inability to deliver multiple treatment cycles. The optimal dose of cyclophosphamide to enable both maximum dose intensity and number of deliverable cycles was determined to be 1500 mg/m 2 ; no further increase in dose from stage I.
Efficacy of treatment
At the time of final follow-up of stages I and II, 13 months after the final patient had completed therapy, 19 of 21 patients treated in stage I and 11 of 14 patients treated in stage II had died, in all but 2 cases due to progressive disease. One of these two patients died of a pulmonary embolus. All patients progressed within six months of being withdrawn from or completing the study.
Fifteen of twenty-one evaluated patients in stage III achieved a CR (71%). Thirteen of these patients remain in remission. Four patients (19%) achieved a PR post treatment. Three of these patients developed progressive disease and subsequently died at 6.5, 9 and 22 months post entry onto the study. The remaining two patients were withdrawn from study after 2 cycles of treatment, one due to progressive disease with subsequent death 3.5 months post enrolment, and the other due to an inadequate response who achieved CR with salvage chemotherapy. At a median follow-up of 44 months from registration, disease-free and overall survival rates of all NHL patients are 76% and 81%, respectively.
Discussion
This study defined that the MTD of epirubicin and cyclophosphamide given in repeated cycles with filgrastim support was 150 mg/m 2 and 1500 mg/m 2 respectively. Although doses of epirubicin of 180 mg/m 2 with cyclophosphamide 1800 mg/m 2 could be given safely as initial treatment in stage I, repeated cycles at these doses resulted in dose limiting thrombocytopenia. The MTD determined and then used in stage III had a projected dose intensity that was double in comparison to standard dose CEOP (epirubicin 75 mg/m 2 , cyclophosphamide 750 mg/m 2 , vincristine 1.4 mg/m 2 ; prednisolone 100 mg/day for 5 days) the actual dose intensity given for all stage III patients was somewhat less than this (85% of the planned dose intensity) due predominantly to hematological toxicity.
The most significant toxicities encountered with the high-dose regimen were hematologic. Grade 4 neutropenia was seen in 72% of all cycles in the NHL patients receiving multiple cycles at the MTD. Febrile neutropenic episodes however, resulted in dose modification after only 5% of cycles in this group. Neutropenic fever occurred much more frequently after the first cycle (67%) compared with subsequent cycles (19%). This may in part relate to dose modification, but this is unlikely to be the sole explanation as only 28% of subsequent cycles were dose modified. An alternative explanation is that prior filgrastim enhanced the marrow to recover more quickly with subsequent cycles, as the duration of neutropenia was shorter in later cycles. While an increasing severity and duration of thrombocytopenia was noted with progressive treatment cycles at the MTD, no significant bleeding episodes were documented and platelet transfusions were required in less than 10% of treatment cycles in this group.
Cardiac toxicity is a potential concern with the administration of high-dose anthracycline regimens [17, 18] . A fall in LVEF to <50% within three months of high-dose chemotherapy (three cycles of epirubicin 200 mg/m 2 , cyclophosphamide 4 g/m 2 ) was described in 8 of the 15 patients treated on a pilot study of the International Breast Cancer Study Group trial [17] , eight of whom also received chest wall radiation therapy. In stages I and II of this study, three patients developed transient cardiac arrhythmias, and another developed apical hypokinesis after the sixth cycle of chemotherapy. In stage III of the study, three patients had a > 12% reduction in LVEF but this did not equate to a fall below the lower normal level. Radiation therapy may have been a contributing factor for two of these patients.
Other non-hematological toxicities were infrequent. Severe mucositis was not observed, consistent with observations that the toxicity profile of dose-escalated epirubicin is better compared with doxorubicin [15] . Grade 3 or 4 nausea, vomiting and diarrhoea were uncommonly reported.
One of the concerns with dose-escalated cyclophosphamide and anthracycline therapy is an increased risk of secondary malignancies, particularly subsequent myelodysplasia or acute leukemia [19, 20, 22] . In the high-dose CHOP study, reported by Shipp et al. [21] , one of the patients developed myelodysplasia with an Ilq23 chromosomal abnormality progressing to acute leukemia with a median follow-up of 20 months. The Scandinavian Breast Cancer Study Group [22] treated 525 patients with loco-regional radiotherapy and either standard-dose or combination standard-dose and highdose chemotherapy. With a median follow-up of 20.2 months, 7 patients developed MDS/AML. None of the patients in our study developed a secondary malignancy, although the numbers are small and the median followup of survivors remains relatively short at 44 months.
The effect of dose-intensive chemotherapy on fertility is a significant concern in younger patients. In stage III of our study premature menopause occurred in all three young women (aged 28-31) evaluated, but ovarian function normalized within two years and one of these women subsequently had a normal pregnancy. We do not know whether this treatment may induce permanent ovarian failure prematurely in older women. Four of our male patients were noted to have oligo-or azoospermia between two to four years post treatment. Although patient numbers in this study are small, the data highlights the need to closely monitor the effects on gonadal function of high-dose anthracycline and cyclophosphamide. Standard dose regimens for intermediate grade lymphoma like CHOP, MACOP-B and VACOP-B have an extremely low incidence of permanent infertility [23, 24] .
This study and the study by Shipp et al. [21] , form part of the limited experience utilizing dose-intensive chemotherapy without stem-cell support for high-risk patients with aggressive NHL. To our knowledge, only one other study has evaluated dose-escalated cyclophosphamide and epirubicin in this setting [25] . In this study maximum dose levels of epirubicin 110 mg/m 2 and cyclophosphamide 1200 mg/m 2 with filgrastim support were administered. Consistent with our experience, no severe non-hematological toxicity but more marked hematological toxicity was observed with increasing dose-intensity.
As a result of this study a multicentre, randomized phase III study is being performed by the Australian and New Zealand Lymphoma Group, comparing highdose and standard dose chemotherapy in patients with advanced, intermediate grade NHL. The high-dose arm comprises the treatment schema used in stage III of this study (high-dose CEOP) versus standard-dose CEOP (epirubicin 75 mg/m 2 , cyclophosphamide 750 mg/m 2 ). This study of high dose-intensity aims to answer the question whether substantial dose-intensification of the most active agents in this disease improves response rates, progression-free survival and overall survival and, if so, at what cost with respect to quality of life, toxicity and resource utilization.
